Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV

Abstract

Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells contribute to the body’s immune defenses. Current chimeric antigen receptor (CAR)-modified T cell immunotherapy shows strong promise for treating various cancers and infectious diseases. Although CARmodified NK cell immunotherapy is rapidly gaining attention, its clinical applications are mainly focused on preclinical investigations using the NK92 cell line. Despite recent advances in CAR-modified T cell immunotherapy, cost and severe toxicity have hindered its widespread use. To alleviate these disadvantages of CAR-modified T cell immunotherapy, additional cytotoxic cell-mediated immunotherapies are urgently needed. The unique biology of NK cells allows them to serve as a safe, effective, alternative immunotherapeutic strategy to CAR-modified T cells in the clinic. While the fundamental mechanisms underlying the cytotoxicity and side effects of CAR-modified T and NK cell immunotherapies remain poorly understood, the formation of the immunological synapse (IS) between CARmodified T or NK cells and their susceptible target cells is known to be essential. The role of the IS in CAR T and NK cell immunotherapies will allow scientists to harness the power of CAR-modified T and NK cells to treat cancer and infectious diseases. In this review, we highlight the potential applications of CAR-modified NK cells to treat cancer and human immunodeficiency virus (HIV), and discuss the challenges and possible future directions of CAR-modified NK cell immunotherapy, as well as the importance of understanding the molecular mechanisms of CAR-modified T cell- or NK cell-mediated cytotoxicity and side effects, with a focus on the CAR-modified NK cell IS.

Key words： natural killer cell; chimeric antigen receptor; immunotherapy; immunological synapse; HIV; cancer

References

1 Ada G (1994) Twenty years into the saga of MHC-restriction. Immunol Cell Biol 72:447–454

2 Adams NM, O’Sullivan TE, Geary CD, Karo JM, Amezquita RA, Joshi NS, Kaech SM, Sun JC (2016) NK cell responses redefine immunological memory. J Immunol 197:2963–2970

3 Aggen DH, Chervin AS, Schmitt TM, Engels B, Stone JD, Richman SA, Piepenbrink KH, Baker BM, Greenberg PD, Schreiber H (2012) Single-chain Valpha Vbeta T-cell receptors function without mispairing with endogenous TCR chains. Gene Ther 19:365–374

4 Akl MR, Nagpal P, Ayoub NM, Prabhu SA, Gliksman M, Tai B, Hatipoglu A, Goy A, Suh KS (2015) Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine. Oncotarget 6:28693–28715

5 Ali A, Kitchen SG, Chen IS, Ng HL, Zack JA, Yang OO (2016) HIV-1-specific chimeric antigen receptors based on broadly neutralizing antibodies. J Virol 90:6999–7006

6 Alter G, Altfeld M (2006) NK cell function in HIV-1 infection. Curr Mol Med 6:621–629

7 Alter G, Altfeld M (2009) NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 265:29–42

8 Alter G, Altfeld M (2011) Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends Immunol 32:219–224

9 Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C (2007) Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204:3027–3036

10 Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, Oniangue-Ndza C, Martin M, Li B, Khakoo SI (2011) HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476:96–100

11 Altfeld M, Gale M Jr (2015) Innate immunity against HIV-1 infection. Nat Immunol 16:554–562

12 Altfeld M, Fadda L, Frleta D, Bhardwaj N (2011) DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 11:176–186

13 Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML, Sykulev Y (2005) Distinct role of lymphocyte function-associated antigen-1 in mediating effective cytolytic activity by cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 102:6437–6442

14 Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 10:625–632

15 Bakker AB, Wu J, Phillips JH, Lanier LL (2000) NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Hum Immunol 61:18–27

16 Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK (2010) The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116:2286–2294

17 Bernstein HB, Wang G, Plasterer MC, Zack JA, Ramasastry P, Mumenthaler SM, Kitchen CM (2009) CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function . Virology 387:59–66

18 Bertolet G, Liu D (2016) The planar lipid bilayer system serves as a reductionist approach for studying NK cell immunological synapses and their functions. Methods Mol Biol 1441:151–165

19 Bhaumik S, Gambhir SS (2002) Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A 99:377–382

20 Biron CA, Byron KS, Sullivan JL (1989) Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320:1731–1735

21 Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H (2013) Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2:e26527

22 Borges da Silva H, Fonseca R, Alvarez JM, D’Imperio Lima MR (2015) IFN-gamma priming effects on the maintenance of effector memory CD4(+) T cells and on phagocyte function: evidences from infectious diseases. J Immunol Res 2015:202816

23 Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML (2001) The immunological synapse. Annu Rev Immunol 19:375–396

24 Bryceson YT, Ljunggren HG (2008) Tumor cell recognition by the NK cell activating receptor NKG2D. Eur J Immunol 38:2957–2961

25 Buck MD, O’Sullivan D, Pearce EL (2015) T cell metabolism drives immunity. J Exp Med 212:1345–1360

26 Burke S, Lakshmikanth T, Colucci F, Carbone E (2010) New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol 31:339–345

27 Campbell KS, Yusa S, Kikuchi-Maki A, Catina TL (2004) NKp44 triggers NK cell activation through DAP12 association that is not influenced by a putative cytoplasmic inhibitory sequence. J Immunol 172:899–906

28 Campi G, Varma R, Dustin ML (2005) Actin and agonist MHCpeptide complex-dependent T cell receptor microclusters as scaffolds for signaling. J Exp Med 202:1031–1036

29 Carr WH, Rosen DB, Arase H, Nixon DF, Michaelsson J, Lanier LL (2007) Cutting edge: KIR3DS1, a gene implicated in resistance to progression to AIDS, encodes a DAP12-associated receptor expressed on NK cells that triggers NK cell activation. J Immunol 178:647–651

30 Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A 100:4120–4125

31 Chehimi J, Bandyopadhyay S, Prakash K, Perussia B, Hassan NF, Kawashima H, Campbell D, Kornbluth J, Starr SE (1991) In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates. J Virol 65:1812–1822

32 Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, Chen L, Wang Y, Wang H, Yi L (2016) A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget 7:27764–27777

33 Chen KH, Wada M, Pinz KG, Liu H, Lin KW, Jares A, Firor AE, Shuai X, Salman H, Golightly M (2017) Preclinical targeting of aggressive T cell malignancies using anti-CD5 chimeric antigen receptor. Leukemia.

34 Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS (2016) Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 126:3130–3144

35 Cho FN, Chang TH, Shu CW, Ko MC, Liao SK, Wu KH, Yu MS, Lin SJ, Hong YC, Chen CH (2014) Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis. PLoS ONE 9:e109352

36 Choi YS, Yang JA, Yusuf I, Johnston RJ, Greenbaum J, Peters B, Crotty S (2013) Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. J Immunol 190:4014–4026

37 Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893–900

38 Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine B, June CH, Schuster SJ (2016) PD-1 blockade modulates chimeric antigen receptor (CAR) modified T cells and induces tumor regression: refueling the CAR. Blood 129 (8):1039–1041

39 Choudhuri K, Llodra J, Roth EW, Tsai J, Gordo S, Wucherpfennig KW, Kam LC, Stokes DL, Dustin ML (2014) Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Nature 507:118–123

40 Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K (2014) CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28:917–927

41 Chung A, Rollman E, Johansson S, Kent SJ, Stratov I (2008) The utility of ADCC responses in HIV infection. Curr HIV Res 6:515–519

42 Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R (2016) HIV reservoirs: what, where and how to target them. Nat Rev Microbiol 14:55–60

43 Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, Baltimore D (1999) The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661–671

44 Cong L, Zhang F (2015) Genome engineering using CRISPR-Cas9 system. Methods Mol Biol 1239:197–217

45 Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823

46 Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A (2002) Defective expression and function of natural killer celltriggering receptors in patients with acute myeloid leukemia. Blood 99:3661–3667

47 Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G (2011) Successful transfer of alloreactive haploidentical KIR ligandmismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118:3273–3279

48 Davis DM (2002) Assembly of the immunological synapse for T cells and NK cells. Trends Immunol 23:356–363

49 Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL (1999) The human natural killer cell immune synapse. Proc Natl Acad Sci U S A 96:15062–15067

50 De Maria A, Moretta L (2008) NK cell function in HIV-1 infection. Curr HIV Res 6:433–440

51 Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, Chun TW, Churchill M, Di Mascio M, Katlama C (2012) Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 12:607–614

52 Della Chiesa M, Romeo E, Falco M, Balsamo M, Augugliaro R, Moretta L, Bottino C, Moretta A, Vitale M (2008) Evidence that the KIR2DS5 gene codes for a surface receptor triggering natural killer cell function. Eur J Immunol 38:2284–2289

53 Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH (2012) Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7:e30264

54 DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271

55 DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin.

56 Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673–1683

57 Dustin ML, Long EO (2010) Cytotoxic immunological synapses. Immunol Rev 235:24–34

58 Dustin ML, Starr T, Varma R, Thomas VK (2007) Unit 18 13 Supported planar bilayers for study of the immunological synapse. Curr Protoc Immunol.

59 Esser R, Muller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schonfeld K (2012) NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. J Cell Mol Med 16:569–581

60 Fadda L, Alter G (2011) KIR/HLA: genetic clues for a role of NK cells in the control of HIV. Adv Exp Med Biol 780:27–36

61 Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT (2012) Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. Clin Dev Immunol 2012:421702

62 Fauci AS, Mavilio D, Kottilil S (2005) NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 5:835–843

63 Fehniger TA, Cooper MA (2016) Harnessing NK cell memory for cancer immunotherapy. Trends Immunol 37:877–888

64 Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, Sacristan C, Victora GD, Zanin-Zhorov A, Dustin ML (2010) Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 28:79–105

65 Funke J, Durr R, Dietrich U, Koch J (2011) Natural killer cells in HIV-1 infection: a double-edged sword. AIDS Rev 13:67–76

66 Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP (2016) GD2-specific CAR T Cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther 24:1135–1149

67 Geldres C, Savoldo B, Dotti G (2016) Chimeric antigen receptorredirected T cells return to the bench. Semin Immunol 28(1):3–9

68 Gilham DE, Debets R, Pule M, Hawkins RE, Abken H (2012) CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18:377–384

69 Gill S, June CH (2015) Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol Rev 263:68–89

70 Gill S, Maus MV, Porter DL (2016) Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev 30:157–167

71 Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016–3026

72 Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U (2015) Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 6:21

73 Gong JH, Maki G, Klingemann HG (1994) Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652–658

74 Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML (1999) The immunological synapse: a molecular machine controlling T cell activation. Science 285:221–227

75 Gras Navarro A, Bjorklund AT, Chekenya M (2015) Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol 6:202

76 Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibodytype specificity. Proc Natl Acad Sci U S A 86:10024–10028

77 Guerrero AD, Moyes JS, Cooper LJ (2014) The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors. Chin J Cancer 33:421–433

78 Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P (2015) CAR-engineered NK Cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci Rep 5:11483

79 Harwood NE, Batista FD (2010) Early events in B cell activation. Annu Rev Immunol 28:185–210

80 Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F (2013) Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis 208:50–56

81 Hayley M, Bourbigot S, Booth V (2011) Self-association of an activating natural killer cell receptor, KIR2DS1. PLoS ONE 6: e23052

82 Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275–1286

83 Hens J, Jennes W, Kestens L (2016) The role of NK cells in HIV-1 protection: autologous, allogeneic or both? AIDS Res Ther 13:15

84 Herberman RB, Nunn ME, Holden HT, Lavrin DH (1975a) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16:230–239

85 Herberman RB, Nunn ME, Lavrin DH (1975b) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 16:216–229

86 Hermanson DL, Kaufman DS (2015) Utilizing chimeric antigen receptors to direct natural killer cell activity. Front Immunol 6:195

87 Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y (2008) CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775–2784

88 Iannello A, Debbeche O, Samarani S, Ahmad A (2008a) Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS. J Leukoc Biol 84:1–26

89 Iannello A, Debbeche O, Samarani S, Ahmad A (2008b) Antiviral NK cell responses in HIV infection: II. Viral strategies for evasion and lessons for immunotherapy and vaccination. J Leukoc Biol 84:27–49

90 Jang JH, Huang Y, Zheng P, Jo MC, Bertolet G, Zhu MX, Qin L, Liu D (2015) Imaging of cell-cell communication in a vertical orientation reveals high-resolution structure of immunological synapse and novel PD-1 dynamics. J Immunol 195:1320–1330

91 Jenkins MR, Tsun A, Stinchcombe JC, Griffiths GM (2009) The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse. Immunity 31:621–631

92 Jiang H, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W (2014) Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Mol Oncol 8:297–310

93 John LB, Kershaw MH, Darcy PK (2013) Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2:e26286

94 Jones RB, Walker BD (2016) HIV-specific CD8(+) T cells and HIV eradication. J Clin Invest 126:455–463

95 Jost S, Altfeld M (2012) Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect 14:904–915

96 Jost S, Altfeld M (2013) Control of human viral infections by natural killer cells. Annu Rev Immunol 31:163–194

97 Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675–678

98 Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704

99 Kershaw MH, Teng MW, Smyth MJ, Darcy PK (2005) Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 5:928–940

100 Kiessling R, Klein E, Pross H, Wigzell H (1975a) “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5:117–121

101 Kiessling R, Klein E, Wigzell H (1975b) “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype . Eur J Immunol 5:112–117

102 Kim YJ, Dubey P, Ray P, Gambhir SS, Witte ON (2004) Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol 6:331–340

103 Kim MG, Kim D, Suh SK, Park Z, Choi MJ, Oh YK (2016) Current status and regulatory perspective of chimeric antigen receptormodified T cell therapeutics. Arch Pharm Res 39:437–452

104 Klingemann H, Boissel L, Toneguzzo F (2016) Natural killer cells for immunotherapy- advantages of the NK-92 cell line over blood NK cells. Front Immunol 7:91

105 Kramski M, Parsons MS, Stratov I, Kent SJ (2013) HIV-specific antibody immunity mediated through NK cells and monocytes. Curr HIV Res 11:388–406

106 Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S, Voigt H, Becker JC, Leng L, Steinle A (2008) Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol 180:7338–7348

107 Kyle RA, Rajkumar SV (2008) Multiple myeloma. Blood 111:2962–2972

108 Lagrue K, Carisey A, Oszmiana A, Kennedy PR, Williamson DJ, Cartwright A, Barthen C, Davis DM (2013) The central role of the cytoskeleton in mechanisms and functions of the NK cell immune synapse. Immunol Rev 256:203–221

109 Lam VC, Lanier LL (2016) NK cells in host responses to viral infections. Curr Opin Immunol 44:43–51

110 Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274

111 Lanier LL, Corliss B, Wu J, Phillips JH (1998a) Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 8:693–701

112 Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH (1998b) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391:703–707

113 Lapteva N, Parihar R, Rollins LA, Gee AP, Rooney CM (2016) Largescale culture and genetic modification of human natural killer cells for cellular therapy. Methods Mol Biol 1441:195–202

114 Le Bert N, Gasser S (2014) Advances in NKG2D ligand recognition and responses by NK cells. Immunol Cell Biol 92:230–236

115 Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, Shaw AS (2002) T cell receptor signaling precedes immunological synapse formation. Science 295:1539–1542

116 Lee KH, Dinner AR, Tu C, Campi G, Raychaudhuri S, Varma R, Sims TN, Burack WR, Wu H, Wang J (2003) The immunological synapse balances T cell receptor signaling and degradation. Science 302:1218–1222

117 Lim WA, June CH (2017) The principles of engineering immune cells to treat cancer. Cell 168:724–740

118 Lisovsky I, Isitman G, Song R, DaFonseca S, Tremblay-McLean A, Lebouche B, Routy JP, Bruneau J, Bernard NF (2015) A higher frequency of NKG2A+ than of NKG2A- NK cells responds to autologous HIV-infected CD4 cells irrespective of whether or not they coexpress KIR3DL1. J Virol 89:9909–9919

119 Liu D, Bryceson YT, Meckel T, Vasiliver-Shamis G, Dustin ML, Long EO (2009) Integrin-dependent organization and bidirectional vesicular traffic at cytotoxic immune synapses. Immunity 31:99–109

120 Liu D, Peterson ME, Long EO (2012) The adaptor protein Crk controls activation and inhibition of natural killer cells. Immunity 36:600–611

121 Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA (2015) Novel CD4-based bispecific chimeric antigen receptor designed for enhanced anti-HIV potency and absence of HIV entry receptor activity. J Virol 89:6685–6694

122 Liu B, Zou F, Lu L, Chen C, He D, Zhang X, Tang X, Liu C, Li L, Zhang H (2016) Chimeric antigen receptor T cells guided by the single-chain Fv of a broadly neutralizing antibody specifically and effectively eradicate virus reactivated from latency in CD4+ T lymphocytes isolated from HIV-1-infected individuals receiving suppressive combined antiretroviral therapy. J Virol 90:9712–9724

123 Liu H, Pa n Y, Meng S, Zhang W, Zhou F (2017a) Current treatment options of T cell-associated immunotherapy in multiple myeloma. Clin Exp Med.

124 Liu X, Zhang Y, Cheng C, Cheng AW, Zhang X, Li N, Xia C, Wei X, Liu X, Wang H (2017b) CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Res 27:154–157

125 Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244

126 Long EO (2008) Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 224:70–84

127 Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, Barbour JD (2008) Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 82:4785–4792

128 Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S (2013) Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31:227–258

129 Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR (2015) 4-1BB costimulation ameliorates Tcell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581–590

130 Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D (2017) Current strategies for the immunotherapy of multiple myeloma. Oncology (Williston Park) 31(1):55–63

131 Magana-Maldonado R, Chavez-Cortez EG, Olascoaga-Arellano NK, Lopez-Mejia M, Maldonado-Leal FM, Sotelo J, Pineda B (2016) Immunological evasion in glioblastoma. Biomed Res Int 2016:7487313

132 Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G (2013) Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36:112–123

133 Marcenaro E, Della Chiesa M, Bellora F, Parolini S, Millo R, Moretta L, Moretta A (2005) IL-12 or IL-4 prime human NK cells to mediate functionally divergent interactions with dendritic cells or tumors. J Immunol 174:3992–3998

134 Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, Trowsdale J (2002) Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31:429–434

135 Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA (2016) Neuroblastoma. Nat Rev Dis Primers 2:16078

136 Maude S, Barrett DM (2016) Current status of chimeric antigen receptor therapy for haematological malignancies. Br J Haematol 172:11–22

137 Mavilio D, Benjamin J, Daucher M, Lombardo G, Kottilil S, Planta MA, Marcenaro E, Bottino C, Moretta L, Moretta A (2003) Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A 100:15011–15016

138 McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 10:11–23

139 Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057

140 Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A (1998) Threedimensional segregation of supramolecular activation clusters in T cells. Nature 395:82–86

141 Morse D, Tannous BA (2012) A water-soluble coelenterazine for sensitive in vivo imaging of coelenterate luciferases. Mol Ther 20:692–693

142 Morvan MG, Lanier LL (2016) NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 16:7–19

143 Mossman KD, Campi G, Groves JT, Dustin ML (2005) Altered TCR signaling from geometrically repatterned immunological synapses. Science 310:1191–1193

144 Mzingwane ML, Tiemessen CT (2017) Mechanisms of HIV persistence in HIV reservoirs. Rev Med Virol.

145 Oelsner S, Friede ME, Zhang C,Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T (2017) Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma. Cytotherapy 19:235–249

146 Ogasawara K, Lanier LL (2005) NKG2D in NK and T cell-mediated immunity. J Clin Immunol 25:534–540

147 Orange JS (2008) Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8:713–725

148 Orange JS (2013) Natural killer cell deficiency. J Allergy Clin Immunol 132, 515–525; quiz 526.

149 Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD, Investigators HIVOS (2006) Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 43:27–34

150 Pallikkuth S, Sharkey M, Babic DZ, Gupta S, Stone GW, Fischl MA, Stevenson M, Pahwa S (2015) Peripheral T follicular helper cells are the major HIV reservoir within central memory CD4 T cells in peripheral blood from chronic HIV infected individuals on cART. J Virol 90(6):2718–2728

151 Pascal V, Yamada E, Martin MP, Alter G, Altfeld M, Metcalf JA, Baseler MW, Adelsberger JW, Carrington M, Anderson SK (2007) Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 infection. J Immunol 179:1625–1633

152 Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G (2013) Follicular helper Tcells serve as the major CD4 Tcell compartment for HIV-1 infection, replication, and production. J Exp Med 210:143–156

153 Pietra G, Vitale C, Pende D, Bertaina A, Moretta F, Falco M, Vacca P, Montaldo E, Cantoni C, Mingari MC (2016) Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. Cancer Immunol Immunother 65:465–476

154 Ping Y, Liu C, Zhang Y (2017) T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell.

155 Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733

156 Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y (2016) Multiplex genome editing to generate universal CAR Tcells resistant to PD1 inhibition. Clin Cancer Res.

157 Rezvani K, Rouce RH (2015) The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6:578

158 Richard J, Sindhu S, Pham TN, Belzile JP, Cohen EA (2010) HIV-1 Vpr up-regulates expressionof ligandsfor theactivatingNKG2Dreceptor and promotes NK cell-mediated killing. Blood 115:1354–1363

159 Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J (1996) Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol 24:406–415

160 Rosenberg EB, McCoy JL, Green SS, Donnelly FC, Siwarski DF, Levine PH, Herberman RB (1974) Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst 52:345–352

161 Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim WA (2016) Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164:770–779

162 Rydyznski C, Daniels KA, Karmele EP, Brooks TR, Mahl SE, Moran MT, Li C, Sutiwisesak R, Welsh RM, Waggoner SN (2015) Generation of cellular immune memory and B-cell immunity is impaired by natural killer cells. Nat Commun 6:6375

163 Sadelain M (2011) Eliminating cells gone astray. N Engl J Med 365:1735–1737

164 Schonfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bonig H, Kohl U, Kloess S (2015) Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 23:330–338

165 Scott-Algara D, Vuillier F, Cayota A, Rame V, Guetard D, Moncany ML, Marasescu M, Dauguet C, Dighiero G (1993) In vitro nonproductive infection of purified natural killer cells by the BRU isolate of the human immunodeficiency virus type 1. J Gen Virol 74(Pt 4):725–731

166 Scully E, Alter G (2016) NK cells in HIV disease. Curr HIV/AIDS Rep 13:85–94

167 Shimizu Y, Geraghty DE, Koller BH, Orr HT, DeMars R (1988) Transfer and expression of three cloned human non-HLA-A, B, C class I major histocompatibility complex genes in mutant lymphoblastoid cells. Proc Natl Acad Sci U S A 85:227–231

168 Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30

169 Siliciano RF (2014) Opening fronts in HIV vaccine development: targeting reservoirs to clear and cure. Nat Med 20:480–481

170 Singh H, Huls H, Kebriaei P, Cooper LJ (2014) A new approach to gene therapy using sleeping beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181–190

171 Smith KM, Wu J, Bakker AB, Phillips JH, Lanier LL (1998) Ly-49D and Ly-49H associate with mouse DAP12 and form activating receptors. J Immunol 161:7–10

172 Stinchcombe JC, Griffiths GM (2003) The role of the secretory immunological synapse in killing by CD8+ CTL. Semin Immunol 15:301–305

173 Stinchcombe JC, Majorovits E, Bossi G, Fuller S, Griffiths GM (2006) Centrosome polarization delivers secretory granules to the immunological synapse. Nature 443:462–465

174 Sun JC, Lopez-Verges S, Kim CC, DeRisi JL, Lanier LL (2011) NK cells and immune “memory”. J Immunol 186:1891–1897

175 Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG (2008) Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329–1337

176 Talmadge JE, Meyers KM, Prieur DJ, Starkey JR (1980) Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J Natl Cancer Inst 65:929–935

177 Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563–1570

178 Topfer K, Cartellieri M, Michen S, Wiedemuth R, Muller N, Lindemann D, Bachmann M, Fussel M, Schackert G, Temme A (2015) DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol 194:3201–3212

179 Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL (2016) Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin.

180 Tozeren A, Sung KL, Sung LA, Dustin ML, Chan PY, Springer TA, Chien S (1992) Micromanipulation of adhesion of a Jurkat cell to a planar bilayer membrane containing lymphocyte functionassociated antigen 3 molecules. J Cell Biol 116:997–1006

181 Tran AC, Zhang D, Byrn R, Roberts MR (1995) Chimeric zetareceptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J Immunol 155:1000–1009

182 Travar M, Petkovic M, Verhaz A (2016) Type I, II, and III interferons: regulating immunity to mycobacterium tuberculosis Infection. Arch Immunol Ther Exp (Warsz) 64:19–31

183 Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, Wyvill KM, Yarchoan R, Pavlakis GN (2002) Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 99:7015–7020

184 Varma R, Campi G, Yokosuka T, Saito T, Dustin ML (2006) T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 25:117–127

185 Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C, Wu J, Heslop HE, Rooney CM, Brenner MK (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108:3890–3897

186 Vinuesa CG (2012) HIV and T follicular helper cells: a dangerous relationship. J Clin Invest 122:3059–3062

187 Virgin HW, Wherry EJ, Ahmed R (2009) Redefining chronic viral infection. Cell 138:30–50

188 Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S (2008) Functions of natural killer cells. Nat Immunol 9:503–510

189 Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44–49

190 Waggoner SN, Reighard SD, Gyurova IE, Cranert SA, Mahl SE, Karmele EP, McNally JP, Moran MT, Brooks TR, Yaqoob F (2016) Roles of natural killer cells in antiviral immunity. Curr Opin Virol 16:15–23

191 Wang RF, Wang HY (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res 27:11–37

192 Wang H, Cao F, De A, Cao Y, Contag C, Gambhir SS, Wu JC, Chen X (2009) Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells 27:1548–1558

193 Ward J, Davis Z, DeHart J, Zimmerman E, Bosque A, Brunetta E, Mavilio D, Planelles V, Barker E (2009) HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of the ATR-mediated DNA damage response. PLoS Pathog 5: e1000613

194 Watzl C, Long EO (2010) Unit 11 19B Signal transduction during activation and inhibition of natural killer cells. Curr Protoc Immunol.

195 Wherry EJ (2011) T cell exhaustion. Nat Immunol 12:492–499

196 Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K (2000) A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922–930

197 Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD (1997) Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor Tcells. Proc Natl Acad Sci U S A 94:11478–11483

198 Yokoyama WM (2008) Mistaken notions about natural killer cells. Nat Immunol 9:481–485

199 Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T (2016) ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J Natl Cancer Inst.

200 Zhen A, Kamata M, Rezek V, Rick J, Levin B, Kasparian S, Chen IS, Yang OO, Zack JA, Kitchen SG (2015) HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol Ther 23:1358–1367

201 Zheng P, Bertolet G, Chen Y, Huang S, and Liu D (2015a) Superresolution imaging of the natural killer cell immunological synapse on a glass-supported planar lipid bilayer. J Vis Exp

202 Zheng P, Noroski LM, Hanson IC, Chen Y, Lee ME, Huang Y, Zhu MX, Banerjee PP, Makedonas G, Orange JS (2015b) Molecular mechanisms of functional natural killer deficiency in patients with partial DiGeorge syndrome. J Allergy Clin Immunol 135:1293–1302